Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead candidate, sabirnetug (ACU193), is a recombinant humanized IgG2 monoclonal antibody designed to selectively target soluble amyloid-beta oligomers (AβOs). Acumen is currently advancing sabirnetug in the Phase 2 ALTITUDE-AD clinical trial and has completed the Phase 1 INTERCEPT-AD trial. The company is also developing an Enhanced Brain Delivery (EBD) technology platform to improve the brain penetration of therapeutic compounds, supporting subcutaneous administration. Acumen has established collaborations with JCR Pharmaceuticals to develop Aβ oligomer-targeted EBD therapies and with Halozyme to develop a subcutaneous formulation of sabirnetug. The company’s scientific approach is based on research into the role of toxic soluble amyloid-beta oligomers in synaptic dysfunction and neurodegeneration.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage acumenpharm.com
Sector Healthcare IR page investors.acumenpharm.com
Tags
alzheimer's disease, monoclonal antibodies, amyloid-beta oligomers, neurodegenerative diseases, immunotherapy, clinical-stage, blood-brain barrier, subcutaneous formulation, disease-modifying therapy, sabirnetug, ACU193, Enhanced Brain Delivery, EBD, JCR Pharmaceuticals, Halozyme, J-Brain Cargo, ALTITUDE-AD, INTERCEPT-AD
Press page —

Metrics

Valuation  
Market cap $ 160.567M
Market cap (USD) $ 160.567M
P/E -1.45
PEG —
P/BV 4.64
P/S —
P/OCF -1.83
P/FCF -1.83
Dividend yield —
Turnover / mcap —
Returns  
ROE -96.2%
ROI -119.4%
ROIC -91.4%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 17.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 122.833M 238.992M 310.125M 196.587M 230.33M 44.429M
Net profit -121.335M -102.329M -52.371M -42.856M -100.606M -7.325M
Free cash flow -115.626M -86.231M -43.085M -35.314M -18.001M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.11 1.72 3.84 5.4 6.76 —
Price performance 12m 0.23 -0.55 -0.29 -0.2 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — — 0.00 8.77M
Lease liabilities (USD) — — 200,000 105,000 1.15M 283,000 150,000
Cash and deposits (USD) 6.55M 43.8M 122M 130M 66.9M 35.6M 54M
Right-of-use assets (USD) — — 200,000 105,000 381,000 266,000 140,000
Net debt (borrowings + leases - cash) (USD) — — — — — -35.3M -45.1M
Cash flow detail
Operating cash flow (USD) — -7.45M -18M -35.2M -43.1M -86.2M -116M
Purchases of property, plant and equipment (USD) — — -40,000 -161,000 -21,000 -16,000 -88,000
Change in payables (cash effect) (USD) — 308,000 557,000 552,000 -261,000 4.27M -5.09M
Interest paid (cash effect) (USD) — 0.00 0.00 0.00 -169,000 -2.97M -2.94M
Income taxes paid (cash effect) (USD) — 0.00 0.00 0.00 0.00 0.00 0.00
Share-based compensation (USD) — 154,000 922,000 3.06M 6.15M 9.64M 9.85M
Free cash flow (OCF - PPE - intangibles) (USD) — — -18M -35.3M -43.1M -86.2M -116M
Income detail
Research and development expense (USD) — 8M 12.3M 32.4M 42.3M 93.8M 105M
↳ 5y CAGR +67.3%
Total comprehensive income (USD) — — -101M -43.4M -51.3M -103M -121M
Comprehensive income to owners (USD) — — -101M -43.4M -51.3M -103M -121M
Reported Aug 16, 2021 Mar 28, 2022 Mar 27, 2023 Mar 27, 2023 Mar 26, 2024 Nov 12, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

As previously disclosed in its Current Report on Form 8-K filed on November 10, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement, dated November 10, 2023 (the “Loan Agreement”), with K2 HealthVentures LLC (the “Lender”). The Loan Agreement provided for a term loan facility (the “Term Loan”) in an aggregate principal amount of $50.0 million, of which the Company borrowed $30.0 million in the first tranche on November 10, 2023. The principal amount of the Term Loan outstanding under the Loan Agreement bore interest per annum at the greater of (i) 9.65% or (ii) the sum of the prime rate last quoted in The Wall Street Journal plus 1.15% for such interest period, and was scheduled to mature on November 1, 2027. The Loan Agreement provided for a final payment fee of an additional $1.6 million (the “Final Payment Fee”) due upon repayment of the Term Loan.

On November 3, 2026, the Company provided notice of its intention to voluntarily prepay in full, using cash on hand, all outstanding obligations under the Loan Agreement in an aggregate amount of approximately $23.3 million (the “Payoff Amount”).

October 30, 2026 at 7:00 AM EDT

Download PDF

-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance --

-- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options --

NEWTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that initial topline data from its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) in participants with early AD did not meet its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either the 35 mg/kg or the 50 mg/kg dose. The trial also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating – Sum of Boxes (CDR-SB), and did not show any meaningful difference between either sabirnetug treatment arm and the placebo arm. Sabirnetug was generally well tolerated, with amyloid-related imaging abnormalities - edema (ARIA-E) observed in ~10% of sabirnetug-treated participants. An analysis of change in amyloid plaque load, as measured by positron emission tomography (PET) SUVr, demonstrated statistically significant amyloid plaque reduction for both dose levels at week 36 and week 76.

Acumen expects to receive and analyze additional data from ALTITUDE-AD in the coming weeks, including fluid biomarker and additional imaging data, but does not expect these data to change the efficacy conclusions of the trial.

Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options, including its Enhanced Brain Delivery™ (EBD®) program. In the interim, the Company plans to take steps to implement cash conservation measures and explore strategic options to maximize shareholder value.

“While we are disappointed the trial did not meet its primary endpoint, we express our compassion and hope for future therapeutic options for patients with Alzheimer’s disease and their families,” said Daniel O’Connell, Chief Executive Officer of Acumen. “We have tremendous gratitude toward the patients, caregivers, investigators and clinical trial sites, as well as all Acumen employees, who worked so diligently over many years on this program.”

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in AD. Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and was evaluated in the Phase 2 ALTITUDE-AD clinical trial in patients with early AD.

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble AβOs for the treatment of AD. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen’s lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, was evaluated in the Phase 2 ALTITUDE-AD clinical trial (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD®) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Forward-Looking Statements

This press release contains forward-looking statements. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193); the anticipated receipt and analysis of additional data from ALTITUDE-AD and Acumen’s expectation that such data will not change the clinical trial’s efficacy conclusions; Acumen’s plans to cease development of sabirnetug; and Acumen’s plans to evaluate its strategic options and take steps to implement cash conservation measures and explore strategic options to maximize shareholder value. These statements are based upon the current beliefs and expectations of Acumen’s management, and are subject to certain factors, risks and uncertainties, including the risk that additional data or further analyses from ALTITUDE-AD may differ from, or change the interpretation of, the topline results, and particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Quarterly Report on Form 10-Q, Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Investors: Alex Braun [email protected]

Media: Robyn Moxon [email protected]

October 26, 2026 at 7:00 AM EDT

Download PDF

  • Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026

  • IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027

  • Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.

“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Another important piece of Acumen’s value proposition is our Enhanced Brain Delivery™ program, combining a validated blood-brain barrier-penetrating technology with an AβO-selective therapeutic antibody. We continue to make progress on IND-enabling activities in support of a mid-2027 IND submission for a lead candidate and remain encouraged about the potential it holds as a next-generation Alzheimer's disease treatment.”

Anticipated Milestones

  • The Company expects to report topline results from ALTITUDE-AD in November 2026.

  • ALTITUDE-AD is a 3-arm Phase 2 study investigating sabirnetug in 542 participants (N=180 per arm) for the treatment of early Alzheimer’s disease.

  • ALTITUDE-AD includes two active doses (35 mg/kg, 50 mg/kg, IV Q4W) vs. placebo over an 18-month double-blinded period.

  • Topline results are expected to include the iADRS (Integrated Alzheimer’s Disease Rating Scale), our primary clinical efficacy endpoint, as well as key secondary endpoints, such as CDR-SB (Clinical Dementia Rating – Sum of the Boxes), certain safety measures such as adverse event rates, including ARIA rates, and key biomarkers.

  • The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.

Third Quarter 2026 Financial Results

  • **Cash Balance.**As of Sept. 30, 2026, cash, cash equivalents and marketable securities totaled $78.6 million compared to cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026. Cash is expected to support current clinical and operational activities into early 2027.

  • **Research and Development (R&D) Expenses.**R&D expenses were $21.1 million for the quarter ended Sept. 30, 2026, compared to $22.0 million for the quarter ended Sept. 30, 2025. The decrease was primarily due to reductions in manufacturing and materials costs and CRO costs, which are both associated with our ALTITUDE-AD clinical trial, and partially offset by increased spending for our EBD program.

  • **General and Administrative (G&A) Expenses.**G&A expenses were $4.7 million for the quarter ended Sept. 30, 2026, compared to $4.5 million for the quarter ended Sept. 30, 2025.

  • **Loss from Operations.**Loss from operations was $25.8 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025. This decrease was due to the decreased R&D expenses over the prior year period.

  • **Net Loss.**Net loss was $25.4 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025.

Conference Call Details

Acumen will host a conference call and live audio webcast today, Oct. 26, 2026, at 8:00 a.m. ET.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in November 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD®) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, Acumen’s plans to develop a candidate to treat Alzheimer's Disease utilizing EBD technology, including its expectations with respect to timing for the submission of an IND, the potential of its EBD candidates and the potential for developing a best-in-class therapeutic candidate for people living with Alzheimer’s Disease. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Prompts

Acumen Pharmaceuticals, Inc. (ticker ABOS), listed in United States.

ETFs Holding Acumen Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 122,212 $ 26.642K Nov 12, 2026
DFSU 0.00% 5,916 $ 1,289.69 Nov 12, 2026
DXUV 0.00% 10,499 $ 2,288.78 Nov 12, 2026
DCOR 0.00% 7,149 $ 1,558.48 Nov 12, 2026
DFAC 0.00% 9,637 $ 2,100.87 Nov 12, 2026